Acylation of Exenatide by Glycolic Acid and its Anti-Diabetic Activities in db/db Mice

被引:0
作者
Rongcai Liang
Xiang Li
Renyu Zhang
Yanan Shi
Aiping Wang
Daquan Chen
Kaoxiang Sun
Wanhui Liu
Youxin Li
机构
[1] Yantai University,School of Pharmacy
[2] Jilin University,College of Life Science
[3] State Key Laboratory of Long-Acting and Targeting Drug Delivery System,School of Pharmacy
[4] Binzhou Medical University,undefined
来源
Pharmaceutical Research | 2014年 / 31卷
关键词
acylation; anti-diabetic activity; exenatide; glycolic acid; stability;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1958 / 1966
页数:8
相关论文
共 134 条
[21]  
Hwang S(1978)Changes in conformation and immunological activity of ovalbumin during its modification with different acid anhydrides Biochim Biophys Acta 536 50-63
[22]  
Son MK(1996)Acylation of the alpha-amino group in neuropeptide Y(12–36) increases binding affinity for the Y2 receptor J Biochem Tokyo 119 37-41
[23]  
Kim YJ(1996)Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine Dev Biol Stand 87 293-306
[24]  
Kim TH(2013)Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres Int J Pharm 454 344-353
[25]  
Lucke A(2013)Stability of Exenatide in poly(D, L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer Eur J Pharm Sci 50 502-510
[26]  
Kiermaier J(2004)Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state Pept Sci 76 298-308
[27]  
Göpferich A(2005)Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: a prototypical example of biopharmaceutical aggregation J Pharm Sci 94 2749-2763
[28]  
Murty SB(2009)Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice Am J Physiol Endocrinol Metab 296 E936-E944
[29]  
Thanoo BC(2012)Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor Exp Diabetes Res 2012 12-16
[30]  
Wei Q(2010)The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics J Control Release 144 10-213